A Phase II Open Label Study of Brentuximab Vedotin in Combination With CHEP in Patients With Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)
Latest Information Update: 24 Sep 2021
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Prednisone (Primary)
- Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Follicular lymphoma; Lymphoproliferative disorders; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- Acronyms PTCL-CHEPA
- 20 Aug 2021 New trial record